In Poland, more and more funding is spent on R&D in companies from the BioTechMed sector. The reason for this is due to the dynamic level of development of enterprises in this industry and the desire to implement new and innovative products on the global market. Larger companies such as Adamed or CelonPharma over the years have developed themselves, collecting funds from the sale of generic drugs and now investing in the development and introduction of new drugs on the market. Smaller companies such as OncoArendi Therapeutics and Blirt, skillfully employ the presently very large government subsidized and the European Union funds for research and the development of technology (e.g. potential new drugs) as well as acquiring patents; for example to sell licenses to pharmaceutical companies. Some of medium-sized companies, such as Mabion, operate in between these two models and seek pharmaceutical partners, with whom they will be able to jointly complete the project and introduce a new product to the market.
For several years LPS has been in close cooperation of drug design with a number of major players in the Polish BioTechMed industry like Adamed and OncoArendi Therapeutics. Our laboratory has been cooperating as a commercial services provider or a partner in application grants. PRO Biostructures provides assistance in obtaining funds from the EU (such as Horizon 2020 – the biggest EU Research and Innovation programme) for the discovery of new molecules using crystallography methods.
OncoArendi Therapeutics Sp. Z o.o is a private biotechnology company founded in 2012. Its activity is focused on the exploration and commercialization of novel molecules. These molecules have the potential to become drugs for cancer and inflammatory diseases.
Adamed began its activities in 1986. Together with Adamed Consumer Healthcare and Polfa Pabianice they formed Adamed Group and created an R&D Innovation department. It is one of the innovation leaders in Poland. It has allocated 200 million PLN for research in the past 5 years. The activities are aimed at developing and patenting new drugs that the company produces using its own resources. For several years Adamed’s goal has been to discover drugs for cancer and to treat the central nervous system.